ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients
This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy optionMRIdian SMART
DENVER, Sept. 7, 2022 -- (Healthcare Sales & Marketing Network) -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRId... Devices, Oncology, Regulatory ViewRay, MRIdian, MRI-guided radiation therapy, radiotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | China Health | Marketing | Pharmaceuticals | Radiation Therapy